VYNE Therapeutics Inc (NASDAQ:VYNE) has a beta value of 1.60 and has seen 2.59 million shares traded in the recent trading session. The company, currently valued at $23.49M, closed the recent trade at $1.41 per share which meant it gained $0.35 on the day or 33.03% during that session. The VYNE stock price is -204.96% off its 52-week high price of $4.30 and 39.72% above the 52-week low of $0.85. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.43 million shares traded. The 3-month trading volume is 271.34K shares.
The consensus among analysts is that VYNE Therapeutics Inc (VYNE) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight.
VYNE Therapeutics Inc (NASDAQ:VYNE) trade information
Sporting 33.03% in the green today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the VYNE stock price touched $1.41 or saw a rise of 2.76%. Year-to-date, VYNE Therapeutics Inc shares have moved -22.52%, while the 5-day performance has seen it change 53.51%. Over the past 30 days, the shares of VYNE Therapeutics Inc (NASDAQ:VYNE) have changed 35.59%. Short interest in the company has seen 0.33 million shares shorted with days to cover at 1.3.
Wall Street analysts have a consensus price target for the stock at $5.75, which means that the shares’ value could jump 75.48% from the levels at last check today.. The projected low price target is $5.75 while the price target rests at a high of $5.75. In that case, then, we find that the latest price level in today’s session is -307.8% off the targeted high while a plunge would see the stock gain -307.8% from the levels at last check today..
VYNE Therapeutics Inc (VYNE) estimates and forecasts
The company’s shares have lost -41.00% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 65.87% over the past 5 years. Earnings growth for 2025 is a modest -13.62% while over the next 5 years, the company’s earnings are expected to increase by 11.71%.
VYNE Dividends
VYNE Therapeutics Inc is expected to release its next earnings report on 2025-May-08 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
VYNE Therapeutics Inc (NASDAQ:VYNE)’s Major holders
Insiders own 8.34% of the company shares, while shares held by institutions stand at 47.62% with a share float percentage of 51.96%. Investors are also buoyed by the number of investors in a company, with VYNE Therapeutics Inc having a total of 45.0 institutions that hold shares in the company. The top two institutional holders are EVENTIDE ASSET MANAGEMENT, LLC with over 1.39 million shares worth more than $3.13 million. As of 2024-06-30, EVENTIDE ASSET MANAGEMENT, LLC held 3.2742% of shares outstanding.
The other major institutional holder is CORMORANT ASSET MANAGEMENT, LP, with the holding of over 1.39 million shares as of 2024-06-30. The firm’s total holdings are worth over $2.75 million and represent 3.2742% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund . As of Mar 31, 2025 , the former fund manager holds about 2.45% shares in the company for having 373.32 shares of worth $0.52 million while later fund manager owns 101.33 shares of worth $0.14 million as of Mar 31, 2025 , which makes it owner of about 0.67% of company’s outstanding stock.
